359 reports of this reaction
4.9% of all BACITRACIN reports
#1 most reported adverse reaction
DRUG HYPERSENSITIVITY is the #1 most commonly reported adverse reaction for BACITRACIN, manufactured by CVS Pharmacy. There are 359 FDA adverse event reports linking BACITRACIN to DRUG HYPERSENSITIVITY. This represents approximately 4.9% of all 7,282 adverse event reports for this drug.
Patients taking BACITRACIN who experience drug hypersensitivity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG HYPERSENSITIVITY is moderately reported among BACITRACIN users, representing a notable but not dominant share of adverse events.
In addition to drug hypersensitivity, the following adverse reactions have been reported for BACITRACIN:
The following drugs have also been linked to drug hypersensitivity in FDA adverse event reports:
DRUG HYPERSENSITIVITY has been reported as an adverse event in 359 FDA reports for BACITRACIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG HYPERSENSITIVITY accounts for approximately 4.9% of all adverse event reports for BACITRACIN, making it one of the most commonly reported side effect.
If you experience drug hypersensitivity while taking BACITRACIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.